Cas9 immunity creates challenges for CRISPR gene editing therapies-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Cas9 immunity creates challenges for CRISPR gene editing therapies

Published:2018-08-29 Issue:1 Volume:9 Page:
ISSN:2041-1723
Container-title:Nature Communications
language:en
Short-container-title:Nat Commun

Author:

Crudele Julie M.,Chamberlain Jeffrey S.

Funder

U.S. Department of Health & Human Services | National Institutes of Health

Muscular Dystrophy Association

Publisher

Springer Science and Business Media LLC

Subject

General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry

Link

http://www.nature.com/articles/s41467-018-05843-9.pdf

Reference15 articles.

1. Cong, L. et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819–823 (2013).

2. Mali, P. et al. RNA-guided human genome engineering via Cas9. Science 339, 823–826 (2013).

3. Wang, H. & Sun, W. CRISPR-mediated targeting of HER2 inhibits cell proliferation through a dominant negative mutation. Cancer Lett. 385, 137–143 (2017).

4. Bengtsson, N. E. et al. Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy. Nat. Commun. 8, 14454 (2017).

5. Charlesworth, C. T. et al. Identification of pre-existing adaptive immunity to Cas9 proteins in humans. Preprint at b ioRxiv https://doi.org/10.1101/243345 (2018).

Cited by 168 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. AAV-based CRISPR-Cas9 genome editing: Challenges and engineering opportunities;Current Opinion in Biomedical Engineering;2024-03

2. CRISPR/Cas9-Mediated Gene Therapy for Glioblastoma: A Scoping Review;Biomedicines;2024-01-21

3. Inhibition of iRhom1 by CD44-targeting nanocarrier for improved cancer immunochemotherapy;Nature Communications;2024-01-04

4. Nanotechnology-based delivery for CRISPR-Cas 9 cargo in Alzheimer's disease;Alzheimer's Disease and Advanced Drug Delivery Strategies;2024

5. CRISPR: the Janus god of modern science;CRISPR-Cas System in Translational Biotechnology;2024

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3